Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

NCT01082549 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01082549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01082549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2010
Completion date
April 30, 2013
Enrollment
780 (actual)
Sites
142

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell lung cancer